Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2022-11-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
华英证券有限责任公司关于深圳信立泰药业股份有限公司控股子公司拟实施股权激励计划暨关联交易的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from a sponsoring securities company regarding a proposed equity incentive plan and related party transaction for a controlling subsidiary of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes comprehensive information about the equity incentive plan, the involved parties, the pricing, the approval process, and the opinions of independent directors and the supervisory board. The document is lengthy (7,841 characters) and contains substantive content about the transaction and its impact, not just an announcement or certification. It is not a general regulatory filing, earnings release, or presentation. The content focuses on a specific transaction involving equity incentives and related party transactions, which is a form of capital/financing update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-11-23 Chinese
关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2022 first extraordinary general meeting (临时股东大会) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes information about the meeting time, location, voting procedures (both onsite and online), agenda items, shareholder registration, and proxy voting instructions. It does not contain financial statements or results but is focused on informing shareholders about the meeting and how to participate and vote on proposals. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document is over 5,000 characters and contains detailed procedural and voting information, not just a brief announcement or a report publication notice. Therefore, the correct classification is PSI with high confidence.
2022-11-23 Chinese
关于董事长叶宇翔先生在特定条件下拟参与控股子公司股权激励计划暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the participation of the company's chairman and other executives in a subsidiary's equity incentive plan, which involves related party transactions and changes in shareholding structure. It details the terms, approvals, and opinions from independent directors and supervisory board, but does not contain financial statements or comprehensive financial data. It is a regulatory announcement about a corporate governance and capital structure related transaction rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about a related party transaction and equity incentive plan.
2022-11-23 Chinese
独立董事关于公司有关事项所发表的独立意见
Board/Management Information Classification · 90% confidence The document is an independent directors' opinion on various company matters, including a subsidiary's equity incentive plan, related party transactions, and the establishment of a special fundraising account. It contains detailed independent opinions and approvals related to corporate governance and compliance with laws and regulations. The document does not contain financial statements or substantive financial data, nor is it a report of financial results or an announcement of voting results. It is a governance-related document expressing independent directors' views on company matters and compliance. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to company governance and management decisions.
2022-11-23 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司董事长叶宇翔先生在特定条件下拟参与控股子公司股权激励计划暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsoring securities company (华英证券有限责任公司) regarding the chairman of Shenzhen Sinocare Inc. (深圳信立泰药业股份有限公司) participating under specific conditions in an equity incentive plan of its controlled subsidiary. It includes comprehensive information about the equity incentive plan, related party transactions, board and independent directors' opinions, supervisory board opinions, and the sponsor's verification opinion. The document contains detailed descriptions of the transaction, pricing policies, risks, and approvals, indicating it is a formal audit or verification report related to a specific transaction rather than a general financial report or announcement. It is not an annual or interim report, earnings release, or a simple announcement. The focus on the sponsor's due diligence and verification of the related party transaction aligns with the definition of an Audit Report / Information (AR). The document length (8340 characters) and content depth support this classification. 9M 2022
2022-11-23 Chinese
关于控股子公司拟实施股权激励计划暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding a proposed equity incentive plan for its controlling subsidiary, Shenzhen Xintai Medical Device Co., Ltd. It details the structure, participants, pricing, and approval process of the equity incentive plan, including related party transactions and board approvals. The document is a formal disclosure of a corporate action involving equity incentives and related party transactions, not a financial report, earnings release, or management discussion. It is not a full annual or interim report, nor a call transcript or audit report. The content fits best with a Capital/Financing Update (CAP) as it involves changes in capital structure through equity incentives and related transactions. The document length (7708 characters) and detailed content support this classification with high confidence.
2022-11-23 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.